NCT06903442 Developing a Brief Intervention to Communicate Cardiovascular Risk to Patients Presenting to the Emergency Department With Chest Pain: a Co-Production Approach. Phase 2.
| NCT ID | NCT06903442 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Edinburgh |
| Condition | Cardiovascular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 118 participants |
| Start Date | 2025-08-25 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 118 participants in total. It began in 2025-08-25 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Some patients who come to the emergency department with chest pain and have not had a heart attack, are at an increased risk of having a heart attack in the future. The investigators know this by taking a blood test (troponin) which looks at damage to the patient's heart. These patients are often sent home from hospital with no information about their risk of heart disease. A patient survey revealed that patients in the emergency department would like to receive more information about heart disease. In this study the investigators will provide patients who are at increased risk of cardiovascular disease with their troponin value. The investigators will deliver this information within a cardiovascular brief intervention, which is a short conversation with a patient about their health. In a previous study the investigators carried out some interviews with patients to find out how their results should be delivered and what information should be included in a cardiovascular brief intervention. The investigators also asked them the best way to provide patients with this information. The aim of this part of the study it to determine if the new cardiovascular brief intervention helps patients understand their risk and if it results in them making changes to their health.
Eligibility Criteria
Inclusion Criteria: * Patients who present to the Emergency Department with symptoms suggestive of acute coronary syndrome * A maximum high-sensitivity cardiac troponin I between 5 ng/L and the sex-specific 99th centile. * Resides in Scotland and has a CHI number * Adults aged 18 and over * No history of cardiovascular disease * At least 1 modifiable cardiovascular risk factor: current smoker, hypertension (140/90 mmHg), hypercholesterolaemia (\>6.0 mmol/L), overweight and obesity (BMI \>25), hyperglycaemia or diabetes mellitus. * Patients who are able to provide informed consent Exclusion Criteria: * Patients with a diagnosis of acute coronary syndrome during index presentation * Patients who are not able to give informed consent * Patients who do not speak English * Patients who are unable to attend hospital as outpatient to receive the cardiovascular brief intervention * Patients with ongoing or planned cardiovascular investigations or interventions * Patients with chronic kidney disease and a eGFR below 30 ml/min
Frequently Asked Questions
Who can join the NCT06903442 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06903442 currently recruiting?
Yes, NCT06903442 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Edinburgh to inquire about joining.
Where is the NCT06903442 trial being conducted?
This trial is being conducted at Edinburgh, United Kingdom.
Who is sponsoring the NCT06903442 clinical trial?
NCT06903442 is sponsored by University of Edinburgh. The trial plans to enroll 118 participants.